Profile data is unavailable for this security.
About the company
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product is Betalutin, a CD37-targeting radio-immunoconjugate designed to advance the treatment of non-Hodgkin lymphoma (NHL). Betalutin uses monoclonal antibodies to attack the cancer cells in two ways, first as an immunotherapy and secondly as a targeting agent for a radioactive payload and is a combination of radiation therapy and immunotherapy. The Company is also leveraging its expertise in radionuclides and CD37-targeting antibodies, along with partners, to build a pipeline of biopharmaceuticals for a range of haematological cancers.
- Revenue in NOK (TTM)0.00
- Net income in NOK-18.56m
- Incorporated2009
- Employees1.00
- LocationThor Medical ASAKjelsasveien 168 BOSLO 0884NorwayNOR
- Phone+47 22183301
- Fax+47 22580007
- Websitehttps://www.nordicnanovector.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Promimic AB | 41.05m | -10.48m | 520.32m | 17.00 | -- | 7.31 | -- | 12.68 | -0.563 | -0.563 | 2.21 | 3.80 | 0.4828 | -3.88 | 3.92 | 2,406,824.00 | -12.33 | -24.89 | -14.16 | -29.25 | 104.60 | 101.23 | -25.54 | -89.47 | 4.51 | -- | 0.00 | -- | 128.63 | -- | 41.95 | -- | -- | -- |
| Arcticzymes Technologies ASA | 108.19m | 7.00m | 679.25m | 68.00 | 97.31 | 2.13 | 52.29 | 6.28 | 0.1367 | 0.1367 | 2.10 | 6.24 | 0.3199 | 0.45 | 1.93 | 1,591,059.00 | 2.07 | 15.58 | 2.19 | 17.22 | 93.99 | 96.69 | 6.47 | 33.23 | 14.95 | -- | 0.0273 | 0.00 | -13.16 | 12.24 | -40.89 | -- | 47.93 | -- |
| Nykode Therapeutics ASA | 68.05m | -419.73m | 887.62m | 179.00 | -- | 0.5272 | -- | 13.04 | -1.35 | -1.35 | 0.2128 | 5.16 | 0.0333 | -- | 1.59 | 393,354.70 | -20.57 | 5.65 | -23.15 | 6.38 | -- | -- | -616.79 | 18.13 | -- | -- | 0.0305 | -- | 79.99 | 282.17 | 17.75 | -- | 187.37 | -- |
| Thor Medical ASA | 0.00 | -18.56m | 985.24m | 1.00 | -- | 3.79 | -- | -- | -0.0873 | 0.021 | 0.00 | 1.11 | 0.00 | -- | -- | 0.00 | -9.82 | -79.17 | -10.54 | -113.94 | -- | -- | -- | -- | -- | -- | 0.0035 | -- | -- | -- | -- | -- | -- | -- |
| Intellego Technologies AB | 231.98m | 83.13m | 1.11bn | 62.00 | 12.81 | 4.73 | 12.19 | 4.77 | 3.03 | 3.03 | 8.50 | 8.20 | 0.8298 | 4.24 | 2.45 | 3,729,807.00 | 29.74 | -- | 37.90 | -- | 68.61 | -- | 35.83 | -- | 1.88 | 8.84 | 0.1532 | -- | 222.74 | -- | 493.56 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -258.87m | 1.28bn | 24.00 | -- | 2.41 | -- | -- | -7.81 | -7.81 | 0.00 | 17.14 | 0.00 | -- | -- | 0.00 | -37.64 | -18.38 | -40.48 | -19.26 | -- | -- | -- | -- | 1.51 | -- | 0.0543 | -- | -- | -- | -36.45 | -- | 2.87 | -- |
| Diamyd Medical AB | 131.42k | -152.33m | 1.28bn | 28.00 | -- | 8.61 | -- | 9,724.09 | -1.60 | -1.60 | 0.0014 | 1.46 | 0.0006 | -- | 3.20 | 4,678.57 | -71.82 | -34.32 | -83.67 | -38.45 | -10,083.21 | -3,111.20 | -115,916.00 | -17,499.13 | -- | -- | 0.1737 | -- | -76.19 | -39.23 | -30.82 | -- | -- | -- |
| Nightingale Health Oyj | 50.27m | -201.44m | 1.28bn | 86.00 | -- | 2.01 | -- | 25.52 | -0.2895 | -0.2895 | 0.0722 | 1.37 | 0.0441 | 2.33 | 3.46 | 50,674.42 | -17.67 | -14.59 | -18.99 | -15.99 | 66.45 | 77.90 | -400.71 | -435.73 | 9.74 | -- | 0.0308 | -- | 4.21 | 16.13 | 3.43 | -- | 8.54 | -- |
| Nanoform Finland Oyj | 26.47m | -249.93m | 1.32bn | 174.00 | -- | 1.62 | -- | 49.95 | -0.2707 | -0.2707 | 0.0285 | 0.829 | 0.0269 | 97.30 | 6.27 | 13,906.00 | -25.39 | -27.13 | -27.55 | -29.48 | -631.53 | -604.26 | -944.30 | -1,023.70 | 8.12 | -- | 0.0778 | -- | -26.41 | 61.31 | 5.98 | -- | 53.92 | -- |
| Cereno Scientific AB | 0.00 | -69.70m | 1.39bn | 5.00 | -- | 5.47 | -- | -- | -0.283 | -0.283 | 0.00 | 0.8998 | 0.00 | -- | -- | 0.00 | -23.45 | -16.81 | -25.41 | -18.26 | -- | -- | -- | -- | -- | -9.44 | 0.1519 | -- | -- | -- | -73.95 | -- | 44.79 | -- |
| Solar Foods Oyj | 199.79k | -123.31m | 1.41bn | 40.00 | -- | 4.33 | -- | 7,056.56 | -0.4438 | -0.4438 | 0.0007 | 1.15 | 0.0004 | -- | 0.0049 | 558.71 | -21.32 | -- | -24.11 | -- | 20,183.14 | -- | -61,719.29 | -- | -- | -2.71 | 0.4266 | -- | -- | -- | -66.44 | -- | -- | -- |
Data as of Nov 25 2024. Currency figures normalised to Thor Medical ASA's reporting currency: Norwegian Krone NOK
0.26%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Storebrand Asset Management ASas of 30 Sep 2024 | 605.65k | 0.26% |
| SSgA Funds Management, Inc.as of 07 Nov 2024 | 2.02k | 0.00% |
Data from 30 Sep 2024 - 31 Oct 2024Source: FactSet Research Systems Inc.
